Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Xconomy: FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data
06:08pm, Monday, 29'th Jun 2020
The FDA has rejected an Intercept Pharmaceuticals drug developed to treat the fatty liver disorder nonalcoholic steatohepatitis, more commonly referred to
FDA turns down Intercept’s long-anticipated NASH drug
05:06pm, Monday, 29'th Jun 2020
The FDA has requested additional data from the company's clinical trial. Intercept's CEO expressed disappointment at the decision, saying the agency had not communicated that the drug, obeticholic aci
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Achieve Life Sciences (ACHV –
Ecco perché oggi il prezzo delle azioni Intercept è crollato del 40% | Invezz
04:26pm, Monday, 29'th Jun 2020
Le azioni di Intercept Pharmaceuticals, Inc (Nasdaq: ICPT) sono precipitate di oltre il 40% dopo che la Food and Drug Administration (FDA) statunitense ha rifiutato di approvare il farmaco dell’azie
Heron Therapeutics (HRTX) Initiated with a Buy at Stifel Nicolaus - Markets
03:44pm, Monday, 29'th Jun 2020
Stifel Nicolaus analyst Derek Archila initiated coverage with a Buy rating on Heron Therapeutics (HRTX – Research Report) today and
Here’s why Intercept stock price collapsed 40% today | Invezz
03:37pm, Monday, 29'th Jun 2020
Shares of Intercept Pharmaceuticals, Inc (Nasdaq: ICPT) plunged over 40% after the U.S. Food and Drug Administration (FDA) declined to approve the firm’s therapy for liver disease. As a result, Inte
FDA Tells Intercept Pharmaceuticals No on Its NASH Drug Candidate -- for Now | The Motley Fool
02:55pm, Monday, 29'th Jun 2020
The pharmaceutical company's attempt to get obeticholic acid approved for the lucrative non-alcoholic steatohepatitis market has hit a (perhaps temporary) roadblock.
Why Intercept Pharmaceuticals Stock Is Crashing Today | The Motley Fool
02:49pm, Monday, 29'th Jun 2020
Shares are taking a step back after the FDA rejected the company's NASH candidate.
Genfit : L'américain Intercept, rival de Genfit, se prend à son tour les pieds dans le tapis
02:32pm, Monday, 29'th Jun 2020
(BFM Bourse) - L'agence américaine du médicament a refusé d'homologuer l'Ocaliva (acide obéticholique) d'Intercept pour le traitement de la fibrose du foie …
Analyst Explains Why They Downgraded Their Rating on Intercept Pharma (ICPT) - Markets
01:29pm, Monday, 29'th Jun 2020
In a report released today, Jay Olson from Oppenheimer downgraded Intercept Pharma (ICPT – Research Report) to Hold, with a
U.S. FDA declines to approve Intercept's NASH therapy; shares plunge
12:58pm, Monday, 29'th Jun 2020
The U.S. Food and Drug Administration declined to approve Intercept Pharmaceuticals Inc's therapy for a progressive liver disease, the company said on Monday, sending its shares down 37% before the be
FDA rejects Intercept Pharma's drug for fatty liver disease
12:28pm, Monday, 29'th Jun 2020
Intercept Pharmaceuticals said Monday that the Food and Drug Administration rejected its drug to treat the fatty liver disease known as NASH.
Enanta Pharmaceuticals Announces the Appointment of Mark G. Foletta to Its Board of Directors | | IT Business Net
12:02pm, Monday, 29'th Jun 2020
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases
Wall Street : Les valeurs à suivre à Wall Street
12:01pm, Monday, 29'th Jun 2020
PARIS (Reuters) - Principales valeurs à suivre lundi à Wall Street, où les contrats à terme sur indices suggèrent une ouverture en hausse de 0,5% environ …
USA-Les valeurs à suivre à Wall Street (actualisé)
11:55am, Monday, 29'th Jun 2020
(Actualisé avec Facebook, Twitter et Snap, annonce de Coty,
Intercept Pharmaceuticals, Gilead, cours en avant-Bourse)
PARIS, 29 juin (Reuters) - Principales valeurs à suivre
lundi à Wall Street
